

**Anti-SOST / Sclerostin Reference Antibody (blosozumab)
Recombinant Antibody
Catalog # APR10302**

Specification

Anti-SOST / Sclerostin Reference Antibody (blosozumab) - Product Information

Application	FC, E, FTA
Primary Accession	O9BQB4
Reactivity	Rat, Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG4SP
Calculated MW	145 KDa

Anti-SOST / Sclerostin Reference Antibody (blosozumab) - Additional Information

Target/Specificity
SOST / Sclerostin

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-SOST / Sclerostin Reference Antibody (blosozumab) - Protein Information

Name SOST ([HGNC:13771](#))

Function
Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.

Cellular Location
Secreted, extracellular space, extracellular matrix

Tissue Location
Widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow


and primary osteoblasts differentiated for 21 days. Detected in the subendothelial layer of the aortic intima (at protein level).

Anti-SOST / Sclerostin Reference Antibody (blosozumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-SOST / Sclerostin Reference Antibody (blosozumab) - Images



Anti-SOST / Sclerostin Reference Antibody (blosozumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-SOST / Sclerostin Reference Antibody (blosozumab) is more than 98.7%, determined by SEC-HPLC.